ReviewCureus2025
Hepatobiliary Cancers in Saudi Arabia From 2000 to 2025.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Focal Hyperechoic Hepatic Lesions in Northern Region of Saudi Arabia: Prevalence, Radiologic Features, and Clinical Relevance.Journal of clinical medicine · 2025Article
- Epidemiology and patterns of GI tract cancers in Saudi Arabia: benefit of prompt lifestyle changes.International journal of clinical and experimental pathology · 2025Review
- Nationwide Prevalence of Hepatocellular Carcinoma in Saudi Arabia: A Population-Based Analysis for 2021.Journal of hepatocellular carcinoma · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatobiliary cancers present a significant challenge to global health. Saudi Arabia and adjacent Gulf nations experience considerable impacts from these cancers. Numerous risk factors have contributed to the increasing prevalence of these cancers. The primary cases are linked to several factors, including hepatitis viral infection, smoking, alcohol consumption, diabetes mellitus, obesity or being overweight, liver cirrhosis, nonalcoholic fatty liver disease, hemochromatosis, aflatoxins, anabolic steroids, and genetic predisposition. Data regarding hepatobiliary cancers is scarcely obtained from Saudi Arabia. This research aims to clarify the epidemiology and risk factors linked to hepatobiliary cancers in Saudi Arabia. Our investigation revealed a lack of studies that collectively examine hepatocellular cancers in Saudi Arabia, highlighting a distinctive element of the current review. To determine the incidence, prevalence, risk factors, and other epidemiological metrics of hepatobiliary cancer in Saudi Arabia, a search was conducted using Medline/PubMed, Scopus, Web of Knowledge, Google Scholar, and relevant public databases that fulfilled the inclusion criteria. An electronic search was conducted using various keywords related to hepatobiliary cancer in Saudi Arabia. In summary, hepatobiliary cancers exhibit significant prevalence in Saudi Arabia, especially liver cancer. Commonly recognized risk factors for type 2 diabetes mellitus encompass tobacco and alcohol consumption, obesity or overweight status, and viral hepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.